BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Ranbaxy Laboratories (RANBAXY.BO) to Expand Mohali Unit to Cater to U.S. Market


12/17/2012 8:20:45 AM

Ranbaxy Laboratories plans to expand its Mohali facility starting 2014, primarily to meet the increase in demand from the US+market&select=1 target=_blank style=text-decoration:none;cursor:hand;>US market. “We will look at adding another block at Mohali in 2014 as we have additional land there,” Ranbaxy’s CEO and Managing Director Arun Sawhney told Business Standard. The drug maker’s existing SEZ (special economic zone) facility in Mohali manufactures oral solid products for export to the US, the European Union and other geographies. The facility is relatively new and received approval from the US regulatory authorities in October last year. However, it assumed significance in Ranbaxy’s operations as its approval had come as a major relief for the company facing long-drawn trouble in its largest market. After Ranbaxy’s three key Indian facilities at Paonta Sahib and Batamandi (both in Himachal Pradesh) along with Dewas (in Madhya Pradesh) came under import alert of the US Food and Drug Administration ( US FDA) in 2008, the company had to shift production of many of its products to its facility in the US — Ohm Laboratories. “This obviously created capacity constraint for the company. Mohali plant approval again provided Ranbaxy a low-cost India-based manufacturing source to supply formulations to the US,” said an analyst. Earlier this year, Ranbaxy started shifting production of its generic version of the world’s bestselling drug Lipitor from the US to its manufacturing facility in Mohali.



   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->